

INFORMAZIONI PERSONALI **Stefano Landi**



 Dipartimento di Biologia, Università' di Pisa. Via Derna, 1. 56126. Pisa



 slandi@biologia.unipi.it

 www.stefanolandi.eu

 Skype: stefanolandi

Sesso Maschile | Data di nascita 09/08/1967 | Nazionalità Italiana; CF: LNDSFN67M09D612X

ESPERIENZE PROFESSIONALI

1/1/2016-attuale **Professore ordinario**
 Dipartimento di Biologia, Università' di Pisa. Via Luca Ghini 13, 56126. Pisa
 Sito web: www.unipi.it

Attività o settore Genetica (BIO/18)

1/1/2012-31/12/2015 **Professore associato**
 Dipartimento di Biologia, Università' di Pisa. Via Luca Ghini 13, 56126. Pisa
 Sito web: www.unipi.it

Attività o settore Genetica (BIO/18)

1/5/2001-31/12/2012 **Ricercatore Universitario**
 Dipartimento di Biologia, Università' di Pisa. Via Luca Ghini 13, 56126. Pisa
 Sito web: www.unipi.it

Attività o settore Genetica (BIO/18)

1/1/2013-31/12/2013 **Consulente come Scientist (WAE, when actually employed)**
 International Agency for Research on Cancer (IARC). 152, Cours Albert Thomas – Lyon, France

Attività o settore Genetics

ISTRUZIONE E FORMAZIONE

12/2000-11/2002 **Borsista post-dottorato, Marie-Curie Individual Fellowship (HPMFCT-2000-00483).**
 European Commission – International Agency for research on Cancer (IARC)

2/2000-11/2000 **Borsista post-dottorato, "Special training award"**

International Agency for Research on Cancer (IARC).

- 11/1999-10/2001 Scuola di Specializzazione in Genetica Applicata 110/100 con lode
Universita' di Pisa
- 02/1998-01/2000 Borsista post-dottorato, "Associateship Award"
US National Research Council, US Environmental Protection Agency (USEPA)
- 04/1997-01/1998 Borsista post-dottorato
Universita' di Pisa - Genetica
- 10/1996-03/1997 Borsa di studio per perfezionamento all'estero
Universita' di Pisa – Finnish Institute of Occupational Health (FIOH), Helsinki (Fin)
- 11/1994-09/1996 Borsa di studio post-dottorato
Universita' di Pisa
- 11/1991-10/1994 Dottorato in Genetica
Universita' di Ferrara
- 06/1991-07/1992 Tirocinio post-lauream per l'abilitazione alla professione di
biologo
Universita' di Pisa
- 06/1991 Laura in Scienze Biologiche 110/100 con lode
Universita' di Pisa
- 06/1986 Diploma di Maturita' Scientifica 51/60
Liceo Scientifico A. Vallisneri (Lucca)

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	intermedio	avanzato	intermedio	avanzato	Avanzato
	Nessuna certificazione disponibile				
Francese	intermedio	avanzato	intermedio	intermedio	Base
	Nessuna certificazione disponibile				

Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato
 Quadro Comune Europeo di Riferimento delle Lingue

ULTERIORI INFORMAZIONI

Attività didattica

- 2002-2003: corso "Genetica II" (Laurea in Scienze Biologiche, Università di Pisa, 5 crediti).
- 2003-2004: corso "Ingegneria Genetica" (Laurea in Scienze Biologiche Molecolari, Facoltà di Pisa, 6 crediti).
- 2004-2010: corso: "Genomica Strutturale e Funzionale" (Laurea specialistica in Scienze e Tecnologie Biomolecolari), Facoltà di Scienze, University of Pisa.
- 2009-2015: corso "Analisi Genetiche e Genomiche" (Laurea in Biologia Molecolare e Cellulare, Facoltà di Scienze (University of Pisa, 6 credits).
- 2012-2015: responsabile del corso "Biologia Generale Modulo II" (corso di laurea in Scienze Naturali e Ambientali, Faculty of Sciences, University of Pisa, 6 credits)
- 2015-attuale: responsabile dei corsi di: Genetica per Scienze Biologiche (9CFU), Analisi Genetiche e Genomiche per la Laurea Magistrale in Biologica molecolare e cellulare (6CFU), Neurogenomics per Corso di Laurea Magistrale in Neurosciences (3 CFU) (Dip. Biologia, Università di Pisa).

Finanziamenti per attività di ricerca

Marie-Curie Reintegration Grant della Commissione Europea (MERG-CT-2004-506373)
 Contratto con "Fondazione Buzzi" Prot. 180 del 2/7/2004
 AIRC- Grant Regionali. N. 1082 del 2005-2007. Co-investigator.
 AIRC- Principal Investigator Grant. N. 1714 del 2005-2006
 NCI (NIH-USA) Grant code R03CA115062, anno 2006-2008. Principal Investigator. Small grants in cancer epidemiology.
 AIRC- Principal Investigator Grant. N. 4601 del 2008-2011
 Finanziamento da "Fondazione Buzzi" Prot. 156 del 25/02/2010 (cod. P22). Years 2010-2013
 PRIN (ex-40%) 2009-2011
 04/2015 –attuale Istituto Toscano Tumori, PI program. Finanziamento per il progetto dal titolo: "Variations in miRNA genes and in miRNA binding sites of DNA repair genes as diagnostic, predictive and prognostic factors of colorectal cancer"
 05/2017-2020 Fondazione Pisa. Diatec-Meso. PI research grant system.

Lista di Pubblicazioni scientifiche su Peer-review journals

See attached list

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Lista delle pubblicazioni su riviste scientifiche con peer-review

- 1: Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, **Landi S**, Lu L, Malecka-Panas E, Mambriani A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nat Genet.* 2015 Aug;47(8):911-6. doi: 10.1038/ng.3341. Epub 2015 Jun 22. PubMed PMID: 26098869; PubMed Central PMCID: PMC4520746.
- 2: Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamrozak K, Dumontet C, Cayuela AJ, Wętek M, **Landi S**, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. *Endocr Relat Cancer.* 2015 Aug;22(4):545-59. doi: 10.1530/ERC-15-0029. Epub 2015 Jun 22. PubMed PMID: 26099684.
- 3: Naccarati A, Rosa F, Vymetalkova V, Barone E, Jiraskova K, Di Gaetano C, Novotny J, Levy M, Vodickova L, Gemignani F, Buchler T, **Landi S**, Vodicka P, Pardini B. Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome. *Oncotarget.* 2016 Apr 26;7(17):23156-69. doi: 10.18632/oncotarget.6804. PubMed PMID: 26735576; PubMed Central PMCID: PMC5029617.
- 4: Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, Melaiu O, De Santi C, Barone E, Elisei R, Seiser E, Innocenti F, Zanger UM, **Landi S**. Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. *Arch Toxicol.* 2016 Dec;90(12):3099-3109. Epub 2016 Jan 19. PubMed PMID: 26783003.
- 5: Figlioli G, Elisei R, Romei C, Melaiu O, Cipollini M, Bambi F, Chen B, Köhler A, Cristaudo A, Hemminki K, Gemignani F, Försti A, **Landi S**. A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2016 Apr;25(4):700-13. doi: 10.1158/1055-9965.EPI-15-0652. Epub 2016 Feb 3. PubMed PMID: 26843521.
- 6: Paolocchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, **Landi S**. Targeting hypoxic response for cancer therapy. *Oncotarget.* 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Review. PubMed PMID: 26859576; PubMed Central PMCID: PMC4924654.
- 7: Thomsen H, Chen B, Figlioli G, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Hoffmann P, Herms S, **Landi S**, Hemminki K, Gemignani F, Försti A. Runs of homozygosity and inbreeding in thyroid cancer. *BMC Cancer.* 2016 Mar 16;16:227. doi: 10.1186/s12885-016-2264-7. PubMed PMID: 26984635; PubMed Central PMCID: PMC4794977.
- 8: Stracquadano G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, Zeron-Medina J, Castro-Giner F, Tomlinson IP, Goding CR, Cygan KJ, Fairbrother WG, Thomas LF, Sætrom P, Gemignani F, **Landi S**, Schuster-Böckler B, Bell DA, Bond GL. The importance of p53 pathway genetics in inherited and somatic cancer genomes. *Nat Rev Cancer.* 2016 Apr;16(4):251-65. doi: 10.1038/nrc.2016.15. Review. PubMed PMID: 27009395.
- 9: Cipollini M, Figlioli G, Maccari G, Garritano S, De Santi C, Melaiu O, Barone E, Bambi F, Ermini S, Pellegrini G, Cristaudo A, Foddìs R, Bonotti A, Romei C, Vivaldi A, Agate L, Molinari E, Barale R, Forsti A, Hemminki K, Elisei R, Gemignani F, **Landi S**. Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. *DNA Repair (Amst).* 2016 May;41:27-31. doi: 10.1016/j.dnarep.2016.03.011. Epub 2016 Mar 31. PubMed PMID: 27062014.
- 10: Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, **Landi S**, Jamrozak K, Dumontet C, Wętek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. *Oncotarget.* 2016 Sep 13;7(37):59029-59048. doi: 10.18632/oncotarget.10665. PubMed PMID: 27437873; PubMed Central PMCID: PMC5312293.
- 11: Campa D, Pastore M, Gentiluomo M, Talar-Wojnarowska R, Kupcinskas J, Malecka-Panas E, Neoptolemos JP, Niesen W, Vodicka P, Delle Fave G, Bueno-de-Mesquita HB, Gazouli M, Pacetti P, Di Leo M, Ito H, Klüter H, Soucek P, Corbo V, Yamao K, Hosono S, Kaaks R, Vashist Y, Gioffreda D, Strobel O, Shimizu Y, Dijk F, Andriulli A, Ivanauskas A, Bugert P, Tavano F, Vodickova L, Zambon CF, Lovecek M, **Landi S**, Key TJ, Boggi U, Pezzilli R, Jamrozak K, Mohelnikova-Duchonova B, Mambriani A, Bambi F, Busch O, Paziienza V, Valente R, Theodoropoulos GE, Hackert T, Capurso G, Cavestro GM, Pasquali C, Basso D, Sperti C, Matsuo K, Büchler M, Khaw KT, Izbicki J, Costello E, Costello E, Michalski C, Stepien A, Rizzato C, Canzian F. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. *Oncotarget.* 2016 Aug 30;7(35):57011-57020. doi: 10.18632/oncotarget.10935. PubMed PMID: 27486979; PubMed Central PMCID: PMC5302969.
- 12: Barone E, Corrado A, Gemignani F, **Landi S**. Environmental risk factors for pancreatic cancer: an update. *Arch Toxicol.* 2016 Nov;90(11):2617-2642. Epub 2016 Aug 18. Review. PubMed PMID: 27538405.
- 13: Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, **Landi MT**, **Landi S**, Le Marchand L, Mambriani A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PH, Peters U, Pezzilli R, Porta M, Purdew M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. *Oncotarget.* 2016 Oct 11;7(41):66328-66343. doi: 10.18632/oncotarget.11041. PubMed PMID: 27579533; PubMed Central PMCID: PMC5340084.
- 14: Maccauda A, Calvetti D, Maccari G, Hemminki K, Försti A, Goldschmidt H, Weinhold N, Houlston R, Andersen V, Vogel U, Buda G, Varkonyi J, Sureda A,

Martinez Lopez J, Watek M, Butrym A, Sarasquete ME, Dudziński M, Jurczynszyn A, Druzd-Sitek A, Kruszewski M, Subocz E, Petrini M, Iskierka-Jażdżewska E, Rażny M, Szombath G, Marques H, Zawirska D, Chraniuk D, Halka J, Hove Jacobsen SE, Mazur G, García Sanz R, Dumontet C, Moreno V, Stępień A, Beider K, Pelosini M, Manuel Reis R, Krawczyk-Kulis M, Rymko M, Avet-Loiseau H, Lesueur F, Grząsko N, Ostrovsky O, Jamrozik K, Vangstedt AJ, Jerez A, Tomczak W, Zaucha JM, Kadar K, Sainz J, Nagler A, **Landi** S, Gemignani F, Canzian F. Identification of miRSNPs associated with the risk of multiple myeloma. *Int J Cancer*. 2017 Feb 1;140(3):526-534. doi: 10.1002/ijc.30465. Epub 2016 Nov 9. PubMed PMID: 27718532.

15: Cipollini M, **Landi** S, Gemignani F. Bonafide Targets of Deregulated microRNAs in Non-Small Cell Lung Cancer as Tool to Identify Novel Therapeutic Targets: A Review. *Curr Pharm Des*. 2017;23(1):55-72. doi: 10.2174/1381612822666161006152838. Review. PubMed PMID: 27719642.

16: Campa D, Capurso G, Pastore M, Talar-Wojnarowska R, Milanetto AC, Landoni L, Maiello E, Lawlor RT, Malecka-Panas E, Funel N, Gazouli M, De Bonis A, Klüter H, Rinzivillo M, Delle Fave G, Hackert T, **Landi** S, Bugert P, Bambi F, Archibugi L, Scarpa A, Katzke V, Dervenis C, Liço V, Furlanello S, Strobel O, Tavano F, Basso D, Kaaks R, Pasquali C, Gentiluomo M, Rizzato C, Canzian F. Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. *Sci Rep*. 2016 Dec 23;6:39565. doi: 10.1038/srep39565. PubMed PMID: 28008994; PubMed Central PMCID: PMC5180167.

17: De Santi C, Vencken S, Blake J, Haase B, Benes V, Gemignani F, **Landi** S, Greene CM. Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing. *PLoS One*. 2017 Jan 26;12(1):e0170999. doi: 10.1371/journal.pone.0170999. eCollection 2017. PubMed PMID: 28125734; PubMed Central PMCID: PMC5268774.

18: Telomeres Mendelian Randomization Collaboration, Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Kurian KM, Pooley KA, Eeles RA, Lee JE, Fang S, Chen WV, Law MH, Bowdler LM, Iles MM, Yang Q, Worrall BB, Markus HS, Hung RJ, Amos CI, Spurdle AB, Thompson DJ, O'Mara TA, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulos A, Onland-Moret NC, Lund E, Duell EJ, Canzian F, Severi G, Overvad K, Gunter MJ, Tumino R, Svenson U, van Rij A, Baas AF, Bown MJ, Samani NJ, van t'Hof FNG, Tromp G, Jones GT, Kuivaniemi H, Elmore JR, Johansson M, McKay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci PM, Neale RE, Olson SH, Gallinger S, Li D, Petersen GW, Risch HA, Klein AP, Han J, Abnet CC, Freedman ND, Taylor PR, Maris JM, Aben KK, Kiemenev LA, Vermeulen SH, Wiencke JK, Walsh KM, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis GR, SanGiovanni JP, Li Y, Mijatovic V, Sapkota Y, Low SK, Zondervan KT, Montgomery GW, Nyholt DR, van Heel DA, Hunt K, Arking DE, Ashar FN, Sotoodehnia N, Woo D, Rosand J, Comeau ME, Brown WM, Silverman EK, Hokanson JE, Cho MH, Hui J, Ferreira MA, Thompson PJ, Morrison AC, Felix JF, Smith NL, Christiano AM, Petukhova L, Betz RC, Fan X, Zhang X, Zhu C, Langefeld CD, Thompson SD, Wang F, Lin X, Schwartz DA, Fingerlin T, Rotter JI, Cotch MF, Jensen RA, Munz M, Dommisch H, Schaefer AS, Han F, Ollila HM, Hillary RP, Albagha O, Ralston SH, Zeng C, Zheng W, Shu XO, Reis A, Uebe S, Hüffmeier U, Kawamura Y, Otowa T, Sasaki T, Hibberd ML, Davila S, Xie G, Siminovich K, Bei JX, Zeng YX, Försti A, Chen B, **Landi** S, Franke A, Fischer A, Ellinghaus D, Flores C, Noth I, Ma SF, Foo JN, Liu J, Kim JW, Cox DG, Delattre O, Mirabeau O, Skibola CF, Tang CS, Garcia-Barcelo M, Chang KP, Su WH, Chang YS, Martin NG, Gordon S, Wade TD, Lee C, Kubo M, Cha PC, Nakamura Y, Levy D, Kimura M, Hwang SJ, Hunt S, Spector T, Soranzo N, Manichaikul AW, Barr RG, Kahali B, Speliotes E, Yerges-Armstrong LM, Cheng CY, Jonas JB, Wong TY, Fogh I, Lin K, Powell JF, Rice K, Relton CL, Martin RM, Davey Smith G. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. *JAMA Oncol*. 2017 May 1;3(5):636-651. doi: 10.1001/jamaoncol.2016.5945. PubMed PMID: 28241208; PubMed Central PMCID: PMC5638008.

19: Mohelnikova-Duchonova B, Strouhal O, Hughes DJ, Holcatova I, Oliverius M, Kala Z, Campa D, Rizzato C, Canzian F, Pezzilli R, Talar-Wojnarowska R, Malecka-Panas E, Sperti C, Federico Zambon C, Pedrazzoli S, Fogar P, Milanetto AC, Capurso G, Delle Fave G, Valente R, Gazouli M, Malleo G, Teresa Lawlor R, Strobel O, Hackert T, Giese N, Vodicka P, Vodickova L, **Landi** S, Tavano F, Gioffreda D, Piepoli A, Paziienza V, Mambriani A, Pedata M, Cantore M, Bambi F, Ermini S, Funel N, Lemstrova R, Soucek P. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. *Sci Rep*. 2017 Mar 8;7:43812. doi: 10.1038/srep43812. PubMed PMID: 28272475; PubMed Central PMCID: PMC5341046.

20: De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddìs R, Cristaudo A, Gemignani F, **Landi** S. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. *Occup Environ Med*. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25. PubMed PMID: 28343162.

21: Campo C, Köhler A, Figlioli G, Elisei R, Romei C, Cipollini M, Bambi F, Hemminki K, Gemignani F, **Landi** S, Försti A. Inherited variants in genes somatically mutated in thyroid cancer. *PLoS One*. 2017 Apr 14;12(4):e0174995. doi: 10.1371/journal.pone.0174995. eCollection 2017. PubMed PMID: 28410400; PubMed Central PMCID: PMC5391920.

22: Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddìs R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, **Landi** S. Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. *Genes Cancer*. 2017 Jan;8(1-2):438-452. doi: 10.18632/genescancer.129. PubMed PMID: 28435517; PubMed Central PMCID: PMC5396622.

23: De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddìs R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, **Landi** S. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. *Sci Rep*. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0. PubMed PMID: 28600498; PubMed Central PMCID: PMC5466648.

24: Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddìs R, Mutti L, Barale R, Gemignani F, Giamas G, **Landi** S. Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. *PLoS One*. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017. PubMed PMID: 28640856; PubMed Central PMCID: PMC5481151.

25: Campa D, Obazee O, Pastore M, Panzuto F, Liço V, Greenhalf W, Katzke V, Tavano F, Costello E, Corbo V, Talar-Wojnarowska R, Strobel O, Zambon CF, Neoptolemos JP, Zerboni G, Kaaks R, Key TJ, Lombardo C, Jamrozik K, Gioffreda D, Hackert T, Khaw KT, **Landi** S, Milanetto AC, Landoni L, Lawlor RT, Bambi F, Pirozzi F, Basso D, Pasquali C, Capurso G, Canzian F. Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. *Cancer Epidemiol Biomarkers Prev*. 2017 Aug;26(8):1349-1351. doi: 10.1158/1055-9965.EPI-17-0075. PubMed PMID: 28765340.

26: Campa D, Pastore M, Capurso G, Hackert T, Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinskas J, Pasquali C, Macinga P, Kaaks R, Stigliano S, Peeters PH, Key TJ, Talar-Wojnarowska R, Vodicka P, Valente R, Vashist YK, Salvia R, Papaconstantinou I, Shimizu Y, Valsuani C, Zambon CF, Gazouli M, Valantiene I, Niesen W, Mohelnikova-Duchonova B, Hara K, Soucek P, Malecka-Panas E, Bueno-de-Mesquita HBA, Johnson T, Brenner H, Tavano F, Fogar P, Ito H, Sperti C, Butterbach K, Latiano A, Andriulli A, Cavestro GM, Busch ORC, Dijk F, Greenhalf W, Matsuo K, Lombardo C, Strobel O, König AK, Cuk K, Strothmann H, Katzke V, Cantore M, Mambriani A, Oliverius M, Pezzilli R, **Landi** S, Canzian F. Do pancreatic cancer and chronic pancreatitis share the same

- genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. *Int J Cancer*. 2018 Jan 15;142(2):290-296. doi: 10.1002/ijc.31047. Epub 2017 Oct 16. PubMed PMID: 28913878.
- 27: Barontini J, Antinucci M, Tofanelli S, Cammalleri M, Dal Monte M, Gemignani F, Vodicka P, Marangoni R, Vodickova L, Kupcinskas J, Vymetalkova V, Forsti A, Canzian F, Stein A, Moreno V, Mastrodonato N, Tavano F, Panza A, Barale R, **Landi S**, Campa D. Association between polymorphisms of TAS2R16 and susceptibility to colorectal cancer. *BMC Gastroenterol*. 2017 Sep 15;17(1):104. doi: 10.1186/s12876-017-0659-9. PubMed PMID: 28915899; PubMed Central PMCID: PMC5603047.
- 28: Obazee O, Capurso G, Tavano F, Archibugi L, De Bonis A, Greenhalf W, Key T, Pasquali C, Milanetto AC, Hackert T, Fogar P, Liço V, Dervenis C, Lawlor RT, Landoni L, Gazouli M, Zambon CF, Funel N, Strobel O, Jamrozziak K, Cantù C, Malecka-Panas E, **Landi S**, Neoptolemos JP, Basso D, Talar-Wojnarowska R, Rinziullo M, Andriulli A, Canzian F, Campa D. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. *Carcinogenesis*. 2018 Mar 8;39(3):360-367. doi: 10.1093/carcin/bgx150. PubMed PMID: 29309705.
- 29: Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocchi E, Zhang M, Canzian F, Childs EJ, Hoskins JW, Jermusyk A, Zhong J, Chen F, Albanes D, Andreotti G, Arslan AA, Babic A, Bamlet WR, Beane-Freeman L, Berndt SI, Blackford A, Borges M, Borgida A, Bracci PM, Brais L, Brennan P, Brenner H, Bueno-de-Mesquita B, Buring J, Campa D, Capurso G, Cavestro GM, Chaffee KG, Chung CC, Cleary S, Cotterchio M, Dijk F, Duell EJ, Foretova L, Fuchs C, Funel N, Gallinger S, M Gaziano JM, Gazouli M, Giles GG, Giovannucci E, Goggins M, Goodman GE, Goodman PJ, Hackert T, Haiman C, Hartge P, Hasan M, Hegyi P, Helzlsouer KJ, Herman J, Holcatova I, Holly EA, Hoover R, Hung RJ, Jacobs EJ, Jamrozziak K, Janout V, Kaaks R, Khaw KT, Klein EA, Kogevinas M, Kooperberg C, Kulke MH, Kupcinskas J, Kurtz RJ, Laheru D, **Landi S**, Lawlor RT, Lee IM, LeMarchand L, Lu L, Malats N, Mambriani A, Mannisto S, Milne RL, Mohelniková-Duchoňová B, Neale RE, Neoptolemos JP, Oberg AL, Olson SH, Orlov I, Pasquali C, Patel AV, Peters U, Pezzilli R, Porta M, Real FX, Rothman N, Scelo G, Sesso HD, Severi G, Shu XO, Silverman D, Smith JP, Soucek P, Sund M, Talar-Wojnarowska R, Tavano F, Thornquist MD, Tobias GS, Van Den Eeden SK, Vashist Y, Visvanathan K, Vodicka P, Wactawski-Wende J, Wang Z, Wentzensen N, White E, Yu H, Yu K, Zeleniuch-Jacquotte A, Zheng W, Kraft P, Li D, Chanock S, Obazee O, Petersen GM, Amundadottir LT. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. *Nat Commun*. 2018 Feb 8;9(1):556. doi: 10.1038/s41467-018-02942-5. PubMed PMID: 29422604; PubMed Central PMCID: PMC5805680.
- 30: Melaiu O, Gemignani F, **Landi S**. The genetic susceptibility in the development of malignant pleural mesothelioma. *J Thorac Dis*. 2018 Jan;10(Suppl 2):S246-S252. doi: 10.21037/jtd.2017.10.41. Review. PubMed PMID: 29507792; PubMed Central PMCID: PMC5830564.
- 31: Barone E, Gemignani F, **Landi S**. Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. *J Thorac Dis*. 2018 Jan;10(Suppl 2):S369-S382. doi: 10.21037/jtd.2017.10.158. Review. PubMed PMID: 29507807; PubMed Central PMCID: PMC5830549.
- 32: Pellè L, Carlsson H, Cipollini M, Bonotti A, Foddìs R, Cristaudo A, Romei C, Elisei R, Gemignani F, Törnqvist M, **Landi S**. The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans. *Arch Toxicol*. 2018 May 10. doi: 10.1007/s00204-018-2211-2. [Epub ahead of print] PubMed PMID: 29748789.
- 33: Campa D, Rizzato C, Stolzenberg-Solomon R, Pacetti P, Vodicka P, Cleary SP, Capurso G, Bueno-de-Mesquita HB, Werner J, Gazouli M, Butterbach K, Ivanauskas A, Giese N, Petersen GM, Fogar P, Wang Z, Bassi C, Ryska M, Theodoropoulos GE, Kooperberg C, Li D, Greenhalf W, Pasquali C, Hackert T, Fuchs CS, Mohelniková-Duchonova B, Sperti C, Funel N, Dieffenbach AK, Wareham NJ, Buring J, Holcátová I, Costello E, Zambon CF, Kupcinskas J, Risch HA, Kraft P, Bracci PM, Pezzilli R, Olson SH, Sesso HD, Hartge P, Strobel O, Malecka-Panas E, Visvanathan K, Arslan AA, Pedrazzoli S, Souček P, Goffreda D, Key TJ, Talar-Wojnarowska R, Scarpa A, Mambriani A, Jacobs EJ, Jamrozziak K, Klein A, Tavano F, Bambi F, **Landi S**, Austin MA, Vodickova L, Brenner H, Chanock SJ, Delle Fave G, Piepoli A, Cantore M, Zheng W, Wolpin BM, Amundadottir LT, Canzian F. The TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. *Int J Cancer*. 2015 May 4. doi: 10.1002/ijc.29590. [Epub ahead of print] PubMed PMID: 25940397.
- 34: Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano S, Foddìs R, Lucchi M, Pellegrini S, Gemignani F, **Landi S**. Expression status of candidate genes in mesothelioma tissues and cell lines. *Mutat Res*. 2015 Jan;771:6-12. doi:10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13. PubMed PMID: 25771974.
- 35: Figlioli G, Chen B, Elisei R, Romei C, Campo C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalembe M, Kula D, Pastor S, Marcos R, Velázquez A, Jarz?b B, **Landi S**, Hemminki K, Gemignani F, F?rsti A. Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. *Sci Rep*. 2015 Mar 10;5:8922. doi: 10.1038/srep08922. PubMed PMID: 25753578; PubMed Central PMCID: PMC4354074.
- 36: Zamora-Ros R, Shivappa N, Steck SE, Canzian F, **Landi S**, Alonso MH, H?bert JR, Moreno V. Dietary inflammatory index and inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. *Genes Nutr*. 2015 Jan;10(1):447. doi:10.1007/s12263-014-0447-x. Epub 2014 Dec 9. PubMed PMID: 25488145; PubMed Central PMCID: PMC4259879.
- 37: Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddìs R, Cristaudo A, **Landi S**. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. *J Thorac Oncol*. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322. PubMed PMID: 25436799.
- 38: Cipollini M, **Landi S**, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in cancer management and research. *Pharmacogenomics Pers Med*. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review. PubMed PMID: 25114582; PubMed Central PMCID: PMC4126202.
- 39: Campa D, Martino A, Varkonyi J, Lesueur F, Jamrozziak K, **Landi S**, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, Garc?ja-Sanz R, Buda G, Gemignani F, R?jos R, Vangsted AJ, Dumontet C, Mart?nez-L?pez J, Moreno MJ, St?pie? A, W?tek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzi?ski M, Weinhold N, Reis RM, Canzian F. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. *Int J Cancer*. 2015 Mar 1;136(5):E351-8. doi: 10.1002/ijc.29101. Epub 2014 Aug 6. PubMed PMID: 25066524.
- 40: Figlioli G, K?hler A, Chen B, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalembe M, Kula D, Pastor S, Marcos R, Velázquez A, Jarz?b B, **Landi S**, Hemminki K, F?rsti A, Gemignani F. Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. *J Clin Endocrinol Metab*. 2014 Oct;99(10):E2084-92. doi:10.1210/jc.2014-1734. Epub 2014 Jul 16. PubMed PMID: 25029422.
- 41: Xu L, Port M, **Landi S**, Gemignani F, Cipollini M, Elisei R, Goudeva L, M?ller JA, Nerlich K, Pellegrini G, Reiners C, Romei C, Schwab R, Abend M, Sturgis EM. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. *Thyroid*. 2014 Jun;24(6):966-74. doi:

10.1089/thy.2013.0566.Epub 2014 May 5. PubMed PMID: 24555500; PubMed Central PMCID: PMC4046192.

42: Martino A, Campa D, Jurczynszyn A, Martı́nez-López J, Moreno MJ, Varkonyi J, Dumontet C, Garcı́a-Sanz R, Gemignani F, Jamrozik K, Stępie? A, Jacobsen SE, Andersen V, Jurado M, **Landi** S, Rossi AM, Lesueur F, Marques H, Dudziński M, Wętek M, Moreno V, Orciuolo E, Petrini M, Reis RM, Rı́os R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. *Cancer Epidemiol Biomarkers Prev*. 2014 Apr;23(4):670-4. doi: 10.1158/1055-9965.EPI-13-1115. Epub 2014 Feb 12. PubMed PMID: 24521996.

43: Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddìs R, Mutti L, Barale R, Gemignani F, Giamas G, **Landi** S. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. *PLoS One*. 2014 Jan 21;9(1):e85935. doi:10.1371/journal.pone.0085935. eCollection 2014. PubMed PMID: 24465798; PubMed Central PMCID: PMC3897543.

44: Pardini B, Rosa F, Barone E, Di Gaetano C, Slyskova J, Novotny J, Levy M, Garritano S, Vodickova L, Buchler T, Gemignani F, **Landi** S, Vodicka P, Naccarati A. Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding. *Clin Cancer Res*. 2013 Nov 1;19(21):6044-56. doi: 10.1158/1078-0432.CCR-13-0314. Epub 2013 Sep 13. PubMed PMID: 24036853.

45: Cipollini M, Figlioli G, Garritano S, Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damici L, Frixia T, **Landi** D, Cancemi L, De Santi C, Melaiu O, Foddìs R, Cristaudo A, Bonotti A, Romei C, Elisei R, Pellegrini G, Barale R, Gemignani F, **Landi** S. Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24. *Cancer Epidemiol Biomarkers Prev*. 2013 Nov;22(11):2121-5. doi: 10.1158/1055-9965.EPI-13-0790. Epub 2013 Sep 5. PubMed PMID: 24008490.

46: Kähler A, Chen B, Gemignani F, Elisei R, Romei C, Figlioli G, Cipollini M, Cristaudo A, Bambi F, Hoffmann P, Herms S, Kalembo M, Kula D, Harris S, Broderick P, Houlston R, Pastor S, Marcos R, Velázquez A, Jarzab B, Hemminki K, **Landi** S, Frsti A. Genome-wide association study on differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2013 Oct;98(10):E1674-81. doi: 10.1210/jc.2013-1941. Epub 2013 Jul 26. PubMed PMID: 23894154.

47: Garritano S, Inga A, Gemignani F, **Landi** S. More targets, more pathways and more clues for mutant p53. *Oncogenesis*. 2013 Jul 1;2:e54. doi:10.1038/oncsis.2013.15. PubMed PMID: 23817466; PubMed Central PMCID: PMC3740285.

48: Cipollini M, Pastor S, Gemignani F, Castell J, Garritano S, Bonotti A, Biarni J, Figlioli G, Romei C, Marcos R, Cristaudo A, Elisei R, **Landi** S, Velázquez A. TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. *Int J Cancer*. 2013 Dec 15;133(12):2843-51. doi:10.1002/ijc.28317. Epub 2013 Jul 13. PubMed PMID: 23754668.

49: Melaiu O, Facioni MS, Cabiati M, Caruso R, Giannessi D, **Landi** S, Gemignani F, Del Ry S. Characterization of novel 3'untranslated regions and related polymorphisms of the gene NPPC, encoding for the C-type natriuretic peptide. *Peptides*. 2013 Jun;44:93-9. doi: 10.1016/j.peptides.2013.03.012. Epub 2013 Mar 28. PubMed PMID: 23542429.

50: Bonotti A, Foddìs R, Papa A, Bigotti M, de Santi C, Gemignani F, **Landi** S, Cristaudo A. [Identification and characterization of microRNA involving in malignant pleural mesothelioma]. *G Ital Med Lav Ergon*. 2012 Jul-Sep;34(3Suppl):552-4. Italian. PubMed PMID: 23405713.

51: Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, Capurso G, Talar-Wojnarowska R, Heller A, Jamrozik K, Khaw KT, Key TJ, Bambi F, **Landi** S, Mohelnikova-Duchonova B, Vodickova L, Böhler MW, Bugert P, Vodicka P, Neoptolemos JP, Werner J, Hoheisel JD, Bauer AS, Giese N, Canzian F. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. *Oncol Rep*. 2013 Apr;29(4):1637-44. doi:10.3892/or.2013.2285. Epub 2013 Feb 12. PubMed PMID: 23403949.

52: Martino A, Sainz J, Manuel Reis R, Moreno V, Buda G, Lesueur F, Marques H, Garcı́a-Sanz R, Rı́os R, Stein A, Dumontet C, Gemignani F, Maria Rossi A, **Landi** S, Jurado M, Petrini M, Jamrozik K, Campa D, Canzian F. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. *J Hum Genet*. 2013 Mar;58(3):155-9. doi: 10.1038/jhg.2012.149. Epub 2013 Jan 10. PubMed PMID: 23303387.

53: Tavanti A, **Landi** S, Senesi S. APEX DNA microarray for the identification of pathogenic fungi. *Methods Mol Biol*. 2013;968:63-70. doi:10.1007/978-1-62703-257-5_4. PubMed PMID: 23296885.

54: Campa D, Rizzato C, Bauer AS, Werner J, Capurso G, Costello E, Talar-Wojnarowska R, Jamrozik K, Pezzilli R, Gazouli M, Khaw KT, Key TJ, Bambi F, Mohelnikova-Duchonova B, Heller A, **Landi** S, Vodickova L, Theodoropoulos G, Bugert P, Vodicka P, Hoheisel JD, Delle Fave G, Neoptolemos JP, Soucek P, Böhler MW, Giese N, Canzian F. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. *Cancer Epidemiol Biomarkers Prev*. 2013 Feb;22(2):320-3. doi: 10.1158/1055-9965.EPI-12-1182. Epub 2012 Dec 18. PubMed PMID: 23250936.

55: Campa D, Rizzato C, Capurso G, Giese N, Funel N, Greenhalf W, Soucek P, Gazouli M, Pezzilli R, Pasquali C, Talar-Wojnarowska R, Cantore M, Andriulli A, Scarpa A, Jamrozik K, Delle Fave G, Costello E, Khaw KT, Heller A, Key TJ, Theodoropoulos G, Malecka-Panas E, Mambri A, Bambi F, **Landi** S, Pedrazzoli S, Bassi C, Pacetti P, Piepoli A, Tavano F, di Sebastiano P, Vodickova L, Basso D, Plebani M, Fogar P, Böhler MW, Bugert P, Vodicka P, Boggi U, Neoptolemos JP, Werner J, Canzian F. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. *Dig Liver Dis*. 2013 Feb;45(2):95-9. doi: 10.1016/j.dld.2012.09.014. Epub 2012 Dec 1. PubMed PMID: 23206934.

56: Figlioli G, **Landi** S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. *Mutat Res*. 2013 Jan-Mar;752(1):36-44. doi: 10.1016/j.mrr.2012.09.002. Epub 2012 Oct 8. Review. PubMed PMID: 23059849.

57: Martino A, Campa D, Jamrozik K, Reis RM, Sainz J, Buda G, Garcı́a-Sanz R, Lesueur F, Marques H, Moreno V, Jurado M, Rı́os R, Szemraj-Rogucka Z, Szemraj J, Tjnneland A, Overvad K, Vangsted AJ, Vogel U, Mikala G, Kdr K, Szombath G, Varkonyi J, Orciuolo E, Dumontet C, Gemignani F, Rossi AM, **Landi** S, Petrini M, Houlston RS, Hemminki K, Canzian F. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. *Br J Haematol*. 2012 Sep;158(6):805-9. doi: 10.1111/j.1365-2141.2012.09244.x. Epub 2012 Jul 24. PubMed PMID: 22823248.

58: Campa D, Martino A, Sainz J, Buda G, Jamrozik K, Weinhold N, Vieira Reis RM, Garcı́a-Sanz R, Jurado M, Rı́os R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, **Landi** S, Canzian F. Comprehensive

- investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. *Br J Haematol.* 2012 May;157(3):331-8. Epub 2012 Feb 13. PubMed PMID: 22590720.
- 59: Di Cianni F, Campa D, Tallaro F, Rizzato C, De Rango F, Barale R, Passarino G, Canzian F, Gemignani F, Montesanto A, **Landi S**, Rose G. MAP3K7 and GSTZ1 are associated with human longevity: a two-stage case-control study using multilocus genotyping. *Age (Dordr).* 2013 Aug;35(4):1357-66. doi:10.1007/s11357-012-9416-8. Epub 2012 May 11. PubMed PMID: 22576335; PubMed Central PMCID: PMC3705096.
- 60: **Landi D**, Gemignani F, **Landi S**. Role of variations within microRNA-binding sites in cancer. *Mutagenesis.* 2012 Mar;27(2):205-10. doi:10.1093/mutage/ger055. PubMed PMID: 22294768.
- 61: **Landi D**, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, Vodickova L, Canzian F, Novotny J, Barale R, **Landi S**. Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome. *Cancer.* 2012 Oct;118(19):4670-80. doi:10.1002/ncr.27435. Epub 2012 Jan 26. PubMed PMID:22282400.
- 62: Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddis R, Gemignani F, Pellegrini S, **Landi S**. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. *Mutat Res.* 2012 Apr-Jun;750(2):132-40. doi:10.1016/j.mrrev.2011.12.003. Epub 2011 Dec 15. Review. PubMed PMID: 22198210.
- 63: Martino A, Campa D, Buda G, Sainz J, Garcia-Sanz R, Jamrozik K, Reis RM, Weinhold N, Jurado M, Rjos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, **Landi S**, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. *Leukemia.* 2012 Jun;26(6):1419-22. doi:10.1038/leu.2011.352. Epub 2011 Dec 20. Erratum in: *Leukemia.* 2013 Jul;27(7):1615-6. PubMed PMID: 22182917.
- 64: Teo MT, **Landi D**, Taylor CF, Elliott F, Vaslin L, Cox DG, Hall J, **Landi S**, Bishop DT, Kiltie AE. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. *Carcinogenesis.* 2012 Mar;33(3):581-6. doi:10.1093/carcin/bgr300. Epub 2011 Dec 12. PubMed PMID: 22166496; PubMed Central PMCID: PMC3291859.
- 65: Martino A, Sainz J, Buda G, Jamrozik K, Reis RM, Garcia-Sanz R, Jurado M, Rjos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, **Landi S**, Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). *Int J Oncol.* 2012 Mar;40(3):625-38. doi:10.3892/ijo.2011.1284. Epub 2011 Dec 6. Review. PubMed PMID: 22159523.
- 66: Cosci B, Vivaldi A, Romei C, Gemignani F, **Landi S**, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, Cappagli V, Viola D, Piaggi P, Vitti P, Pinchera A, Elisei R. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. *Endocr Relat Cancer.* 2011 Sep 20;18(5):603-12. doi:10.1530/ERC-11-0117. Print 2011 Oct. PubMed PMID:21810974.
- 67: Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Gemignani F, **Landi S**. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels. *Int J Biol Markers.* 2011 Apr-Jun;26(2):117-23. doi:10.5301/IJBM.2011.8332. PubMed PMID: 21574151.
- 68: Cancemi L, Romei C, Bertocchi S, Tarrini G, Spitaleri I, Cipollini M, **Landi D**, Garritano S, Pellegrini G, Cristaudo A, Pinchera A, Barale R, Elisei R, **Landi S**, Gemignani F. Evidence that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. *Int J Cancer.* 2011 Dec 15;129(12):2816-24. doi:10.1002/ijc.25937. Epub 2011 Apr 25. PubMed PMID: 21520031.
- 69: **Landi D**, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, Canzian F, Barale R, Gemignani F, **Landi S**. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. *Mutat Res.* 2011 Dec;717(1-2):109-15. doi:10.1016/j.mrfmmm.2010.10.002. Epub 2010 Oct 30. Review. PubMed PMID: 20971123.
- 70: **Landi D**, Barale R, Gemignani F, **Landi S**. Prediction of the biological effect of polymorphisms within microRNA binding sites. *Methods Mol Biol.* 2011;676:197-210. doi:10.1007/978-1-60761-863-8_14. PubMed PMID: 20931399.
- 71: Maccari G, Gemignani F, **Landi S**. COMPASS (COMplex PAttern of Sequence Search Software), a simple and effective tool for mining complex motifs in whole genomes. *Bioinformatics.* 2010 Jul 15;26(14):1777-8. doi:10.1093/bioinformatics/btq258. Epub 2010 May 25. PubMed PMID: 20501554.
- 72: Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, Barale R, Gemignani F, **Landi S**. DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. *Hum Mutat.* 2010 Apr;31(4):456-65. doi:10.1002/humu.21214. PubMed PMID: 20127977.
- 73: Dumontet C, **Landi S**, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, Gemignani F. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. *Bone Marrow Transplant.* 2010 Aug;45(8):1316-24. doi:10.1038/bmt.2009.335. Epub 2009 Dec 7. PubMed PMID: 19966851.
- 74: Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, **Landi D**, **Landi S**, Zhou Y, Liu H. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. *Carcinogenesis.* 2009 Dec;30(12):2064-9. doi:10.1093/carcin/bgp283. Epub . PubMed PMID: 19917630.
- 75: Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, LeCalvez-Kelm F, Brugi, res L, Vargas FR, Brentani RR, Ashton-Prolla P, **Landi S**, Tavtigian SV, Hainaut P, Achatz MI. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. *Hum Mutat.* 2010 Feb;31(2):143-50. doi:10.1002/humu.21151. PubMed PMID: 19877175.
- 76: Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, **Landi D**, Gemignani F, **Landi S**. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. *Occup Environ Med.* 2010 Apr;67(4):233-6. doi:10.1136/oem.2009.049205. Epub 2009 Oct 26. PubMed PMID: 19858537.

- 77: Gemignani F, Neri M, Bottari F, Barale R, Canessa PA, Canzian F, Ceppi M, Spitaleri I, Cipollini M, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Ugolini D, Mutti L, Bonassi S, **Landi** S. Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. *Mutat Res.* 2009 Dec 1;671(1-2):76-83. doi:10.1016/j.mrfmmm.2009.09.003. Epub 2009 Sep 12. PubMed PMID: 19751749.
- 78: Costa B, Pini S, Martini C, Abelli M, Gabelloni P, **Landi** S, Muti M, Gesi C, Lari L, Cardini A, Galderisi S, Mucci A, Lucacchini A, Cassano GB. Ala147T substitution in translocator protein is associated with adult separation anxiety in patients with depression. *Psychiatr Genet.* 2009 Apr;19(2):110-1. doi:10.1097/YPG.0b013e32832080f6. PubMed PMID: 19668118.
- 79: Armani C, **Landi** S, Nuti M, Di Stefano R, Balbarini A. HAS-1 genetic polymorphism in sporadic abdominal aortic aneurysm. *Heart Int.* 2009 Jun;30(4):e1. doi: 10.4081/hi.2009.e1. PubMed PMID: 21977277; PubMed Central PMCID: PMC3184700.
- 80: Lagani V, Montesanto A, Di Cianni F, Moreno V, **Landi** S, Conforti D, Rose G, Passarino G. A novel similarity-measure for the analysis of genetic data in complex phenotypes. *BMC Bioinformatics.* 2009 Jun 16;10 Suppl 6:S24. doi:10.1186/1471-2105-10-S6-S24. PubMed PMID: 19534750; PubMed Central PMCID: PMC2697648.
- 81: Costa B, Pini S, Gabelloni P, Abelli M, Lari L, Cardini A, Muti M, Gesi C, **Landi** S, Galderisi S, Mucci A, Lucacchini A, Cassano GB, Martini C. Oxytocin receptor polymorphisms and adult attachment style in patients with depression. *Psychoneuroendocrinology.* 2009 Nov;34(10):1506-14. doi:10.1016/j.psyneuen.2009.05.006. Epub 2009 Jun 9. PubMed PMID: 19515497.
- 82: Pardini B, Naccarati A, Polakova V, Smerhovsky Z, Hlavata I, Soucek P, Novotny J, Vodickova L, Tomanova V, **Landi** S, Vodicka P. NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic. *Mutat Res.* 2009 Jun;666(1-2):64-7. doi: 10.1016/j.mrfmmm.2009.04.004. Epub 2009 Apr 22. PubMed PMID: 19393249.
- 83: Polakova V, Pardini B, Naccarati A, **Landi** S, Slyskova J, Novotny J, Vodickova L, Bermejo JL, Hanova M, Smerhovsky Z, Tulupova E, Kumar R, Hemminki K, Vodicka P. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. *Hum Mutat.* 2009 Apr;30(4):661-8. doi:10.1002/humu.20931. PubMed PMID: 19224585.
- 84: Garritano S, Gemignani F, Voegelé C, Nguyen-Dumont T, Le Calvez-Kelm F, DeSilva D, Lesueur F, **Landi** S, Tavtigian SV. Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. *BMC Genet.* 2009 Feb 17;10:5. doi: 10.1186/1471-2156-10-5. PubMed PMID: 19222838; PubMed Central PMCID: PMC2648999.
- 85: **Landi** S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. *Mutat Res.* 2009 Mar-Jun;681(2-3):299-307. doi: 10.1016/j.mrrev.2008.12.001. Epub 2008 Dec 27. Review. PubMed PMID: 19150414.
- 86: Betti M, Neri M, Ferrante D, **Landi** S, Biava A, Gemignani F, Bertolotti M, Mirabelli D, Padoan M, Ugolini D, Botta M, Bonassi S, Magnani C, Dianzani I. Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. *Int J Hyg Environ Health.* 2009 May;212(3):322-9. doi:10.1016/j.ijheh.2008.08.001. Epub 2008 Oct 1. PubMed PMID: 18838334.
- 87: Neri M, Ugolini D, Dianzani I, Gemignani F, **Landi** S, Cesario A, Magnani C, Mutti L, Puntoni R, Bonassi S. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. *Mutat Res.* 2008 Jul-Aug;659(1-2):126-36. doi: 10.1016/j.mrrev.2008.02.002. Epub 2008 Feb 23. Review. PubMed PMID: 18420450.
- 88: **Landi** D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, F'rsti A, Hemminki K, Canzian F, **Landi** S. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. *Carcinogenesis.* 2008 Mar;29(3):579-84. doi: 10.1093/carcin/bgm304. Epub 2008 Jan 12. PubMed PMID: 18192692.
- 89: Campa D, Tavanti A, Gemignani F, Mogavero CS, Bellini I, Bottari F, Barale R, **Landi** S, Senesi S. DNA microarray based on arrayed-primer extension technique for identification of pathogenic fungi responsible for invasive and superficial mycoses. *J Clin Microbiol.* 2008 Mar;46(3):909-15. Epub 2007 Dec 26. PubMed PMID: 18160452; PubMed Central PMCID: PMC2268329.
- 90: **Landi** D, Gemignani F, Barale R, **Landi** S. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. *DNA Cell Biol.* 2008 Jan;27(1):35-43. PubMed PMID: 17941804.
- 91: Ugolini D, Neri M, Ceppi M, Cesario A, Dianzani I, Filiberti R, Gemignani F, **Landi** S, Magnani C, Mutti L, Puntoni R, Bonassi S. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. *Mutat Res.* 2008 Mar-Apr;658(3):162-71. Epub 2007 Aug 10. Review. PubMed PMID: 17904414.
- 92: Gheit T, Billoud G, de Koning MN, Gemignani F, Forslund O, Sylla BS, Vaccarella S, Franceschi S, **Landi** S, Quint WG, Canzian F, Tommasino M. Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect Beta papillomavirus types. *J Clin Microbiol.* 2007 Aug;45(8):2537-44. Epub 2007 Jun 20. PubMed PMID: 17581938; PubMed Central PMCID: PMC1951219.
- 93: Bottari F, **Landi** S, Gemignani F. Single tube genotyping of GSTM1, GSTT1 and TP53 polymorphisms by multiplex PCR. *DNA Seq.* 2006 Oct;17(5):396-9. PubMed PMID: 17343214.
- 94: **Landi** S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F, Canessa PA, Canzian F, Ceppi M, Filiberti R, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Mutti L, Puntoni R. Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. *Int J Cancer.* 2007 Jun 15;120(12):2739-43. PubMed PMID: 17290392.
- 95: Gemignani F, **Landi** S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gaborieau V, Gioia-Patricola L, Bellini I, Barale R, Canzian F, Hall J, Boffetta P, Hung RJ, Brennan P. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. *Carcinogenesis.* 2007 Jun;28(6):1287-93. Epub 2007 Jan 27. PubMed PMID: 17259654.
- 96: **Landi** S, Bottari F, Gemignani F, Gioia-Patricola L, Guino E, Osorio A, de Oca J, Capella G, Canzian F, Moreno V; Bellvitge Colorectal Cancer Study

- Group. Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. *Eur J Cancer*. 2007 Mar;43(4):762-8. Epub 2007 Jan 26. PubMed PMID:17258448.
- 97: Landi S, Gemignani F, Canzian F, Gaborieau V, Barale R, Landi D, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gioia-Patricola L, Hall J, Boffetta P, Hung RJ, Brennan P. DNA repair and cell cycle control genes and the risk of young-onset lung cancer. *Cancer Res*. 2006 Nov 15;66(22):11062-9. PubMed PMID: 17108146.
- 98: Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella G, Boldrini L, Canzian F, Moreno V. Polymorphisms within inflammatory genes and colorectal cancer. *J Negat Results Biomed*. 2006 Oct24;5:15. PubMed PMID: 17062130; PubMed Central PMCID: PMC1634873.
- 99: Hung RJ, Boffetta P, Canzian F, Moullan N, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Landi S, Gemignani F, Hall J, Brennan P. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. *Cancer Res*. 2006 Aug 15;66(16):8280-6. PubMed PMID: 16912209.
- 100: Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. *Cancer Epidemiol Biomarkers Prev*. 2006 Jun;15(6):1126-31. PubMed PMID: 16775170.
- 101: Gheit T, Landi S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, Canzian F, Tommasino M. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. *J Clin Microbiol*. 2006 Jun;44(6):2025-31. PubMed PMID: 16757593; PubMed Central PMCID: PMC1489390.
- 102: Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, Gonzalez S, Guino E, Capella G, Canzian F. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. *Clin Cancer Res*. 2006 Apr 1;12(7 Pt 1):2101-8. PubMed PMID: 16609022.
- 103: Stankov K, Landi S, Gioia-Patricola L, Bonora E, Volante M, Papotti M, Romeo G. GSTT1 and M1 polymorphisms in H₂O₂-sensitive thyroid cancer patients. *Cancer Lett*. 2006 Aug 18;240(1):76-82. Epub 2006 Jan 20. PubMed PMID: 16427734.
- 104: Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chaj^š V, Clavel-Chapelon F, T^hard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quir^çs JR, Larra^ñaga N, Mart^ínez-Garc^ía C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. *Br J Cancer*. 2006 Jan 30;94(2):299-307. PubMed PMID: 16404426; PubMed Central PMCID: PMC2361124.
- 105: Gemignani F, Landi S, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, Cambray M, Capella G, Canzian F. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul;14(7):1633-8. PubMed PMID: 16030094.
- 106: Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. *Pharmacogenet Genomics*. 2005 Aug;15(8):535-46. PubMed PMID: 16006997.
- 107: Landi S, Gemignani F, Monnier S, Canzian F. A database of single-nucleotide polymorphisms and a genotyping microarray for genetic epidemiology of lung cancer. *Exp Lung Res*. 2005 Mar;31(2):223-58. PubMed PMID: 15824023.
- 108: Gemignani F, Landi S, Chabrier A, Smet A, Zehbe I, Canzian F, Tommasino M. Generation of a DNA microarray for determination of E6 natural variants of human papillomavirus type 16. *J Virol Methods*. 2004 Aug;119(2):95-102. PubMed PMID:15158590.
- 109: Bonassi S, Lando C, Ceppi M, Landi S, Rossi AM, Barale R. No association between increased levels of high-frequency sister chromatid exchange cells (HFCs) and the risk of cancer in healthy individuals. *Environ Mol Mutagen*. 2004;43(2):134-6. PubMed PMID: 14991754.
- 110: Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gut^írr^ez-Enr^íquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. *Oncogene*. 2004 Mar 11;23(10):1954-6. PubMed PMID: 14647431.
- 111: Landi S, Gemignani F, Gioia-Patricola L, Chabrier A, Canzian F. Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. *Biotechniques*. 2003 Oct;35(4):816-20, 822, 824-7. PubMed PMID:14579748.
- 112: Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. *Cancer Res*. 2003 Jul 1;63(13):3560-6. PubMed PMID: 12839942.
- 113: Landi S, Naccarati A, Ross MK, Hanley NM, Dailey L, Devlin RB, Vasquez M, P^egram RA, DeMarini DM. Induction of DNA strand breaks by trihalomethanes in primary human lung epithelial cells. *Mutat Res*. 2003 Jul 8;538(1-2):41-50. PubMed PMID: 12834753.
- 114: Naccarati A, Zanello A, Landi S, Consigli R, Migliore L. Sperm-FISH analysis and human monitoring: a study on workers occupationally exposed to styrene. *Mutat Res*. 2003 Jun 6;537(2):131-40. PubMed PMID: 12787818.
- 115: Gemignani F, Perra C, Landi S, Canzian F, Kurg A, T^änⁱsson N, Galanello R, Cao A, Metspalu A, Romeo G. Reliable detection of beta-thalassemia and G6PD mutations by a DNA microarray. *Clin Chem*. 2002 Nov;48(11):2051-4. PubMed PMID:12406995.
- 116: Gemignani F, Landi S, Vivant F, Zienolddiny S, Brennan P, Canzian F. A catalogue of polymorphisms related to xenobiotic metabolism and cancer susceptibility. *Pharmacogenetics*. 2002 Aug;12(6):459-63. PubMed PMID: 12172214.

- 117: Gemignani F, **Landi** S, DeMarini DM, Kole R. Spontaneous and MNNG-induced reversion of an EGFP construct in HeLa cells: an assay for observing mutations in living cells by fluorescent microscopy. *Hum Mutat.* 2001 Dec;18(6):526-34. PubMed PMID: 11748845.
- 118: DeMarini DM, **Landi** S, Tian D, Hanley NM, Li X, Hu F, Roop BC, Mass MJ, Keohavong P, Gao W, Olivier M, Hainaut P, Mumford JL. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. *Cancer Res.* 2001 Sep 15;61(18):6679-81. PubMed PMID: 11559534.
- 119: DeMarini DM, **Landi** S, Ohe T, Shaughnessy DT, Franz, n R, Richard AM. Mutation spectra in Salmonella of analogues of MX: implications of chemical structure for mutational mechanisms. *Mutat Res.* 2000 Sep 20;453(1):51-65. PubMed PMID:11006412.
- 120: **Landi** S, Iazzolino E, Barale R. Are baseline frequencies of SCEs, CAs, and MN in human lymphocytes related to hematological values? *Mutat Res.* 2000 Aug 21;469(1):159-66. PubMed PMID: 10946252.
- 121: Shaughnessy DT, Ohe T, **Landi** S, Warren SH, Richard AM, Munter T, Franz, n R, Kronberg L, DeMarini DM. Mutation spectra of the drinking water mutagen 3-chloro-4-methyl-5-hydroxy-2(5H)-furanone (MCF) in Salmonella TA100 and TA104: comparison to MX. *Environ Mol Mutagen.* 2000;35(2):106-13. PubMed PMID: 10712744.
- 122: **Landi** S, Barale R. Sister chromatid exchanges, chromosome aberrations and micronuclei in female lymphocytes: correlations with biological rhythms, miscarriages and contraceptive pill use. *Mutagenesis.* 1999 Nov;14(6):581-6. PubMed PMID: 10567033.
- 123: **Landi** S, Hanley NM, Kligerman AD, DeMarini DM. Induction of sister chromatid exchanges in human peripheral blood lymphocytes by bromoform: investigation of the role of GSTT1-1 polymorphism. *Mutat Res.* 1999 Oct 19;429(2):261-7. PubMed PMID: 10526210.
- 124: Ohe T, Shaughnessy DT, **Landi** S, Terao Y, Sawanishi H, Nukaya H, Wakabayashi K, DeMarini DM. Mutation spectra in Salmonella TA98, TA100, and TA104 of two phenylbenzotriazole mutagens (PBTA-1 and PBTA-2) detected in the Nishitakase River in Kyoto, Japan. *Mutat Res.* 1999 Oct 19;429(2):189-98. PubMed PMID:10526204.
- 125: **Landi** S, Frenzilli G, Milillo PC, Cocchi L, Sbrana I, Scapoli C, Barale R. Spontaneous sister chromatid exchange and chromosome aberration frequency in humans: the familial effect. *Mutat Res.* 1999 Aug 18;444(2):337-45. PubMed PMID:10521673.
- 126: **Landi** S, Hanley NM, Warren SH, Pegram RA, DeMarini DM. Induction of genetic damage in human lymphocytes and mutations in Salmonella by trihalomethanes: role of red blood cells and GSTT1-1 polymorphism. *Mutagenesis.* 1999 Sep;14(5):479-82. PubMed PMID: 10473651.
- 127: **Landi** S, Norppa H, Frenzilli G, Cipollini G, Ponzanelli I, Barale R, Hirvonen A. Individual sensitivity to cytogenetic effects of 1,2:3,4-diepoxybutane in cultured human lymphocytes: influence of glutathione S-transferase M1, P1 and T1 genotypes. *Pharmacogenetics.* 1998 Dec;8(6):461-71. PubMed PMID: 9918129.
- 128: Barale R, Chelotti L, Davini T, Del Ry S, Andreassi MG, Ballardini M, Bulleri M, He J, Baldacci S, Di Pede F, Gemignani F, **Landi** S. Sister chromatid exchange and micronucleus frequency in human lymphocytes of 1,650 subjects in an Italian population: II. Contribution of sex, age, and lifestyle. *Environ Mol Mutagen.* 1998;31(3):228-42. PubMed PMID: 9585261.
- 129: Barale R, Marrazzini A, Bacci E, Di Sibio A, Tessa A, Cocchi L, Scarcelli V, Lubrano V, Vassalle C, **Landi** S. Sister chromatid exchange and micronucleus frequency in human lymphocytes of 1,650 subjects in an Italian population: I. Contribution of methodological factors. *Environ Mol Mutagen.* 1998;31(3):218-27. PubMed PMID: 9585260.
- 130: Ponzanelli I, **Landi** S, Bernacchi F, Barale R. The nature of high frequency sister chromatid exchange cells (HFCs). *Mutagenesis.* 1997 Sep;12(5):329-33. PubMed PMID: 9379910.
- 131: **Landi** S, Ponzanelli I, Cipollini G, Frenzilli G, Luccini A, Milillo CP, Sbrana I, Barale R. Modulating factors of individual sensitivity to diepoxybutane: chromosome aberrations induced in vitro in human lymphocytes. *Mutagenesis.* 1997 Jan;12(1):17-22. PubMed PMID: 9025092.
- 132: : **Landi** S, Frenzilli G, Sbrana I, Barale R. Modulating factors of individual sensitivity to diepoxybutane: sister chromatid exchanges induced in vitro in human lymphocytes. *Mutat Res.* 1996 Oct 25;357(1-2):75-82. PubMed PMID: 8876682.
- 133: : **Landi** S, Ponzanelli I, Hirvonen A, Norppa H, Barale R. Repeated analysis of sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes: effect of glutathione S-transferase T1 and M1 genotype. *Mutat Res.* 1996 Mar 26;351(1):79-85. PubMed PMID: 8602177.
- 134: : Ponzanelli I, **Landi** S, Barale R. Persistence of 4-nitroquinoline-1-oxide induced lesions in human lymphocytes. *Mutat Res.* 1996 Feb 15;362(2):193-7. PubMed PMID: 8596538.
- 135: : **Landi** S, Ponzanelli I, Barale R. Effect of red cells and plasma blood in determining individual lymphocytes sensitivity to diepoxybutane assessed by in vitro induced sister chromatid exchanges. *Mutat Res.* 1995 Nov;348(3):117-23. PubMed PMID: 8524363.
- 136: : Ponzanelli I, **Landi** S, Barale R. Use of three-way differential staining and liquid holding for the assessment of individual repair capacity. *Mutat Res.* 1995 Feb;346(2):93-7. PubMed PMID: 7533894.
- 137: : Sbrana I, Luccini A, **Landi** S, Barale R. Enhancement of SCE frequency by alpha-naphthoflavone in cultured lymphocytes in relation to environmental factors. *Environ Mol Mutagen.* 1995;26(4):331-7. PubMed PMID: 8575422.

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della L. 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 01 Giugno 2018.